Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster
Open Access
- 16 February 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (4) , 786-790
- https://doi.org/10.1093/jac/dkl562
Abstract
Infections due to multidrug-resistant (MDR) Gram-negative pathogens in the ICU have prompted the use of colistin, an antibiotic forgotten for decades. The aim of this retrospective observational study was to record and present the emergence of colistin-resistant Klebsiella pneumoniae (CRKB) in a Greek ICU. In a new university tertiary hospital, the first patients admitted in the ICU were already colonized or infected with MDR pathogens, and this led to frequent colistin use as part of empirical or microbiologically documented therapy. Colistin resistance was defined as MIC >4 mg/L by the Etest method. All CRKB isolated in surveillance cultures or clinical specimens in the ICU during the period 2004–5 were recorded along with patients' characteristics. Eighteen CRKB were isolated from 13 patients over a 16 month period, representing either colonizing or infective isolates. Patients' mean age was 70 years, with a mean APACHE II score at admission of 22. They all had a long hospitalization (median 69 days) and a long administration of colistin (median 27 days). Colistin-resistant isolates were implicated as pathogens in two bacteraemias, a ventilator-associated pneumonia and two soft tissue infections. Repetitive extragenic palindromic PCR identified six distinct clones, and horizontal transmission was also documented. Selective pressure due to extensive or inadequate colistin use may lead to the emergence of colistin resistance among K. pneumoniae isolates, jeopardizing treatment options in the ICU, potentially increasing morbidity and mortality of critically ill patients and necessitating prudent use of colistin.Keywords
This publication has 12 references indexed in Scilit:
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Panresistance in VIM-1-producing Klebsiella pneumoniaeJournal of Antimicrobial Chemotherapy, 2005
- Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaPublished by Elsevier ,2004
- First identification of an Escherichia coli clinical isolate producing both metalloβ-lactamase VIM-2 and extended-spectrum β-lactamase IBC-1Clinical Microbiology & Infection, 2004
- Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection controlJournal of Infection, 2003
- Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobactet speciesClinical Microbiology & Infection, 2001
- Distribution of repetitive DNA sequences in eubacteria and application to finerpriting of bacterial enomesNucleic Acids Research, 1991
- Association between colistin resistance and broad-spectrum recipient deficiency in Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 1986
- Effects of Oral Antibiotics on Stool Flora and Overall Sensitivity Patterns in an Intensive Care NurseryPediatric Research, 1982